Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Update
by Doug Wharley · The Cerbat GemVirax Biolabs Group Limited (NASDAQ:VRAX – Get Free Report) was the target of a large growth in short interest in the month of December. As of December 15th, there was short interest totaling 149,941 shares, a growth of 639.2% from the November 30th total of 20,284 shares. Currently, 6.3% of the company’s shares are sold short. Based on an average daily trading volume, of 27,512,123 shares, the days-to-cover ratio is currently 0.0 days. Based on an average daily trading volume, of 27,512,123 shares, the days-to-cover ratio is currently 0.0 days. Currently, 6.3% of the company’s shares are sold short.
Analyst Ratings Changes
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Virax Biolabs Group in a research note on Tuesday, October 14th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $3.00.
View Our Latest Stock Report on VRAX
Virax Biolabs Group Stock Performance
Shares of Virax Biolabs Group stock traded up $0.01 during trading on Wednesday, reaching $0.36. The company had a trading volume of 86,753 shares, compared to its average volume of 1,541,276. Virax Biolabs Group has a fifty-two week low of $0.35 and a fifty-two week high of $3.20. The firm’s fifty day moving average is $0.50 and its 200-day moving average is $0.67.
Virax Biolabs Group (NASDAQ:VRAX – Get Free Report) last announced its quarterly earnings data on Tuesday, December 2nd. The company reported ($0.27) earnings per share for the quarter. The company had revenue of $0.00 million during the quarter.
Virax Biolabs Group Company Profile
Virax Biolabs Group (NASDAQ: VRAX) is a clinical-stage biotechnology company focused on the research, development and manufacturing of next-generation vaccines targeting respiratory and other infectious diseases. Headquartered in Australia, the company leverages advanced viral vector platforms to create novel immunization solutions designed to induce both systemic and mucosal immunity. Virax Biolabs is publicly traded on the NASDAQ exchange under the symbol VRAX.
At the core of Virax Biolabs’ pipeline is a proprietary adenoviral vector platform, licensed exclusively from a leading academic institution, which serves as the backbone for intranasal and injectable vaccine candidates.